It's melanoma.

Now what?

Know your risk and navigate your melanoma journey with confidence.

DecisionDx-Melanoma offers clarity, answers, and confidence

A melanoma diagnosis can feel overwhelming. You might be wondering what it means—and what comes next. That’s where DecisionDx-Melanoma comes in: a test available for patients diagnosed with stage I–III cutaneous melanoma, helping to bring clarity and confidence to your care.

Using a small sample from your original tissue biopsy, this genetic test looks at your tumor’s biology to provide personalized insights into how your melanoma may behave—for example, how likely it is to spread or come back. With this personalized approach, your provider can create a care plan customized for you, helping you move forward in your treatment plan with confidence.

   

Hear how melanoma survivors found clarity and guidance with the DecisionDx-Melanoma test.

Represents the only melanoma genomic test shown to be associated with improved patient survival1

Uses your tumor biology to deliver personalized insights to help guide more precise care

Offers coverage through Medicare and many private insurers, with an market-leading financial assistance program.

A physician's perspective on personalized melanoma care

Learn how the DecisionDx-Melanoma test is changing the way some physicians approach melanoma prognosis. In this short video, Dr. Abel Jarrell explains how the test goes beyond traditional factors to reveal each tumor’s unique biology—with the goal of bringing peace of mind to low-risk patients and helping identify high-risk cases that may need additional treatment or follow-up.

Frequently asked questions

By better understanding the risk of your individual tumor biology, your provider can make better management decisions. The bottom line? More personalized treatment leads to better outcomes.

Not all GEP tests are the same. DecisionDx-Melanoma is the only test that can provide you with a comprehensive test result that gives you a clinically validated, personalized risk assessment. DecisionDx-Melanoma is the only test with over 200,000 patients studied and 50 peer-reviewed publications

The value of a test is driven by the value of information it provides. DecisionDx-Melanoma has continued to show that it offers data that is above and beyond what traditional staging can provide. 

Other
GEP tests
Identifies patient risk for nodal metastasis
Provides personalized risk for sentinel lymph node positivity x
Provides personalized risk of recurrence including MSS, RFS, and DMFS x
Data demonstrates independent, significant risk stratification provided by GEP result compared to AJCC stage x
Data demonstrates improved patient survival associated with testing x

DecisionDx-Melanoma is supported by over 50 peer-reviewed publications. Check out our abundance of clinical data here.

Take the next step - your voice matters in your care

Wherever you are in your melanoma journey, you deserve clarity. Ask your doctor about DecisionDx-Melanoma and take the next step toward informed, confident care.

Advocate for yourself: How DecisionDx-Melanoma impacted a patient's treatment journey

Leah Bressler, a melanoma survivor, shares how the DecisionDx-Melanoma test provided answers and peace of mind during her diagnosis. With critical insights into her tumor biology, her care team was able to customize her treatment plan and change the course of her care.

   

"What I would tell someone who is going through this diagnosis is to get the DecisionDx-Melanoma test, advocate for themselves, talk to their provider about it."
- Leah Bressler, Melanoma Survivor

Your melanoma. Your future.

Feel empowered on your journey—ask your doctor about DecisionDx-Melanoma today

References

  1. Bailey et al.  JCO PO. 2023
  2. Ahmed K, et al. Cancer Medicine. 2021.
  3. Block, et al. JADPRO. 2023